{"filing":{"accession_number":"0001104659-26-097226","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623190d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/tm2623190d1_8k.htm"},"events":[{"id":27966,"run_id":25545,"accession_number":"0001104659-26-097226","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Traws Pharma disclosed Q2 2026 financial results via press release on August 14, 2026, reporting zero revenue, R\u0026D expenses of $1.1M, G\u0026A expenses of $3.5M, and a net loss of $3.0M for the quarter ($0.16 per share), with cash and equivalents of $5.0M as of June 30, 2026.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29705,"accession_number":"0001104659-26-097226","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Traws Pharma via a press release issued on August 14, 2026, including revenue ($0), R\u0026D expenses ($1.1M for Q2), G\u0026A expenses ($3.5M for Q2), and net loss ($3.0M for Q2, or $0.16 per share). The exhibit includes condensed consolidated balance sheets and statements of operations with comparative periods. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:40:54.766020+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29705,"accession_number":"0001104659-26-097226","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Traws Pharma via a press release issued on August 14, 2026, including revenue ($0), R\u0026D expenses ($1.1M for Q2), G\u0026A expenses ($3.5M for Q2), and net loss ($3.0M for Q2, or $0.16 per share). The exhibit includes condensed consolidated balance sheets and statements of operations with comparative periods. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:40:54.766020+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-08-14"}]}